Corcept Therapeutics (CORT) Stock Price & Analysis

CORT$79.22—
Medical - PharmaceuticalsGrowth Stock
Compare
Market cap$7.98BEnterprise value$8.47BRevenue (TTM)$963.65MMarket position—

Score

66
Bullish
Value
54
Quality
59
Growth
84

AI Analysis

Snapshot

Corcept Therapeutics is a growth-led story right now — Growth 84/100 is the pillar doing the heavy lifting (overall 66/100) in Medical - Pharmaceuticals. Under the hood: P/E 52.8, rich vs its own history, plus revenue compounding ~24% annually over recent years. Street targets still imply ~68% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

54
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

84
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

59
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Corcept Therapeutics Incorporated (CORT) last printed $79.22. Equity value is $7.98B. Trailing earnings multiple 49.27. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$81.32M$159.2M$251.25M$306.49M$353.87M$365.98M$401.86M$482.38M$675.04M$761.41M

About

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.

Corcept Therapeutics (CORT) Stock Price & Analysis

CORT price $79.22 —

Ticker
CORT
Price
$79.22
Change
—
Market cap
$7.98B
P/E
49.27
Forward P/E
16.49
Dividend yield
0.00%
Beta
0.45
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Stocklytics score
66
Value
54
Quality
59
Growth
84

Stocklytics score rationale: value 54, quality 59, growth 84.

AI Score 75. Corcept Therapeutics has a strong gross profit margin of approximately 75.6% and a net profit margin of about 16.8%, indicating solid profitability. However, its high price-to-earnings ratio of approximately 52.8 suggests that the stock may be overvalued relative to its earnings, despite a favorable growth outlook as reflected in its revenue growth in recent quarters

Insights · Forecast · Financials · Learn

Stocklytics home · Screener